ELITE 2022 Entrepreneurs Josh Cohen and Justin Klee of Amylyx Pharmaceuticals

Josh Cohen

Co-CEO and Co-Founder, Amylyx Pharmaceuticals

Justin Klee

Co-CEO and Co-Founder, Amylyx Pharmaceuticals

Advancing a Potential Treatment for ALS

In 2013, a single question began what would later become Amylyx Pharmaceuticals’ ongoing mission: “Why do neurons die, and how can we prevent this from happening?” Less than a decade later, Josh Cohen and Justin Klee have overseen the development of an investigational product for the potential treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. It was their work on that investigational product that earned them an ELITE award in our Drug Researchers and Developers category in 2020, and since then Justin and Josh have only continued the rapid growth of Amylyx as part of their ongoing commitment to support the neurodegenerative community.

Amylyx has grown to more than 200 employees and launched its upsized IPO while continuing clinical and regulatory development of its potential therapy for the treatment of ALS. This investigational therapy was accepted for priority review by the FDA and is under review with Health Canada and the European Medicines Agency. Josh and Justin have been at the helm of driving this progress for, and with, the community of people with ALS, their caregivers, researchers, and others in this space.

Amylyx’ unyielding persistence and openness to listen to and hear the voices of the community is central to their mission to advance solutions to address significant unmet needs, including a lack of treatment options, which is a key element of the shared goals of Amylyx employees throughout the company. They created positions for care coordinators and patient support specialists as they develop their practices, grow their team, and continue their community-centric approach.

This year, Amylyx was presented with the first Morris ALS/MND Principles Accolade Certificate in recognition of their Expanded Access Program, and in 2021, the company was recognized by the ALS Association’s Gold West Chapter as recipients of the Essey Commitment to Cures Award. Josh and Justin were also honorees of the 2021 Henri Termeer Transatlantic Connections Award.

These recent achievements are a testament to what Justin and Josh set out to do nearly a decade ago—advance solutions and potential treatment options to give people living with neurodegenerative diseases more moments with the ones they love.


You May Also Like

Ignored Caregivers Suffer from an Information Void

Over the course of the last several years, pharma companies have tailored their messaging ...

ELITE 2020 Transformational Leader Claire Loran of Otsuka America Pharmaceutical, Inc.

Claire Loran Senior Manager, Marketing Operations Otsuka America Pharmaceutical, Inc. Solving Business Challenges We ...

ELITE 2020 Marketing Team Edwards Lifesciences’ Disease Awareness Team

Edwards Lifesciences’ Disease Awareness Team Edwards Lifesciences Creative Agency: Fishawack Health dba Carling Communications ...